Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$115.93M+1506.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bahija Jallal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 524
- Beta
- 0.74
- Country
- GB
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.26
Financials
Revenue
$115.93M+1506.7%Net Income
$-808.0KEBITDA
$3.57MFree Cash Flow
$-6.26MEPS (diluted)
$-0.02Shares Outstanding (diluted)
50.97M-76.2%Operating Expenses
$117.83MCash & Debt
$880.21MRevenue by Segment (annual)
$400.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $297.57M | $-26.42M | $-0.53 |
| 2024 | $247.98M | $-40.81M | $-1.02 |
| 2023 | $197.39M | $-43.75M | $-0.89 |
| 2022 | $144.23M | $-43.46M | $-0.95 |
| 2021 | $27.04M | $-133.45M | $-3.13 |
| 2020 | $30.11M | $-74.09M | $-2.33 |
| 2019 | $25.67M | $-103.93M | $-3.81 |
| 2018 | $23.65M | $-71.63M | $-2.62 |
| 2017 | $14.45M | $-49.57M | $-20.16 |
| 2016 | $16.46M | $-23.13M | $-9.45 |
| 2015 | $11.46M | $13.45M | $0.00 |
| 2014 | $6.38M | $-5.59M | $-2.53 |
| 2013 | $2.04M | $-3.69M | $0.00 |
Valuation
IMCRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-55.94%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·21d ago·Positive
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
…rall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TE…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
… Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September…
View source ↗ - Newszacks.com·41d ago·Positive
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026? Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
View source ↗ - Newszacks.com·56d ago·Neutral
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
View source ↗ - Newszacks.com·56d ago·Positive
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation? Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
View source ↗ - Newszacks.com·56d ago·Neutral
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.16 per share
Typical surprise +4.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.02 vs $-0.01miss
- Wed, May 6$0.25 vs $-0.26beat
- Wed, Feb 25$-0.60 vs $-0.28miss
- Thu, Nov 6$0.02 vs $-0.30beat
- Thu, Aug 7$-0.20 vs $-0.21beat
- Wed, May 7$0.10 vs $-0.35beat
Estimates and results for IMCR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMCR officers and directors.
- Bought
- $24.0m
- Sold
- $12.4m
4 trades
20 trades
- Jallal Bahijasold
- Goll Johnsold
- St Leger Tina Ambersold
- Berman David Msold
- Berman David Msold
- Berman David Msold
- Berman David Msold
- Berman David Msold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMCR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.